Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS
While the majority of adverse events were mild and self-limiting, there were instances of severe events that could have led to hospitalization or even fatalities. It is crucial to actively prioritize primary safety research on sparsentan, with a particular focus on cohort event monitoring, to better understand and establish causal relationships between the treatment and reported adverse events.
Authors
- Zixing Huang (ORCID: https://orcid.org/0000-0001-7967-5948)
- Jiahui Li (ORCID: https://orcid.org/0009-0008-9565-7967)
- Hongxuan Fan (ORCID: https://orcid.org/0000-0002-1234-544X)
- Boda Zhou (ORCID: https://orcid.org/0000-0001-8207-7367)
- Yafen Yang
Institutions
- Shanxi Medical University (CN)
- Second Hospital of Shanxi Medical University (CN)
- Beijing Tsinghua Chang Gung Hospital (CN)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1007/s40620-025-02412-4
- Citations
- 1
- Primary Topic
- S100 Proteins and Annexins
- Type
- article
- Field-Weighted Citation Impact
- 0.81